To further demonstrate the neutralizing capacity of the anti-IFN Ab, we activated HC PBMC with LPS or LPS + IFN in the presence of 20% control or NTM/COV+ patient serum, measuring IL-12 levels after 24-h incubation. D IFN recovery in the presence of autologous patient (NTM/COV+) serum: 20% control or patient serum was added to RPMI-containing recombinant IFN and IFN levels were determined by Luminex. The capacity of patient serum to neutralize recombinant IFN was further confirmed by adding 20% of control or patient serum to RPMI-containing recombinant IFN and measuring IFN levels by Luminex. Experiments looking at the effects of patient serum on levels of exogenously administered IFN demonstrated no detectable free IFN following incubation with serum (Figure 1D). [Extracted from the article]